Specialist Doctor Nesrin Aslan Ilkmen

Education

1995 – 1999
Department of Nuclear Medicine, Faculty of Medicine, Osmangazi University

1986 – 1992
Faculty of Medicine, Anadolu University

Professional Experience

2023
Nuclear Medicine Department, Istanbul Florence Nightingale Hospital

2022
Lecturer, Department of Nuclear Medicine, Faculty of Medicine, Biruni University

2011
Neolife Medical Center

2010 – 2011
Sonomed Imaging Center, Nuclear Medicine Department

2007 – 2010
Kartal Koşuyolu High Specialty Education and Research Hospital, Nuclear Medicine Department

1999 – 2007
Acıbadem Kadıköy Hospital, Nuclear Medicine Department

Professional Trainings

2014
JCI Quality Management System

2011
Hospital Management Certificate Program (SIEMENS Academy)

2005
ISO Quality System Management

Memberships

Turkish Society of Nuclear Medicine (TSNM)
Private Hospitals and Health Institutions Association (OHSAD)
Health Insurance Association (SASDER)
Quality Association (KALDER)

Scientific Publications

Published articles in international peer-reviewed journals:

1. Diagnostic efficacy of preoperative lymphoscintigraphy, Ga-67 scintigraphy, and computed tomography for detection of lymph node metastasis in cases with ovarian or endometrial carcinoma. S Ozalp, O T Yalcin, S Polay, N Aslan, E Vardareli, B Adapinar. Acta Obstet Gynecol Scand. 1999 Feb;78(2):155-9.
2. Lesion detectability and clinical effectiveness of dual-head coincidence gamma camera imaging in comparison with dedicated PET systems in tumor patients. Narin Y, Urhan M, Canpolat N, Vardereli E, Bayhan H. J Int Med Res. 2007 Jul-Aug;35(4):467-73.
3. Extended rituximab schedules may result in increased efficacy in pulmonary malt lymphoma. Seker M, Bilici A, Ustaalioglu BO, Salman T, Sonmez B, Canpolat NA, Salepci T, Gumus M, Yaylaci M. Leuk Res. 2009 Sep;33(9): e154-6. Epub 2009 Apr 21.
4. Is there a cut-off value for standardized uptake values in positron emission tomography for predicting response to treatment and survival in patients with advanced non-small cell lung cancer? Single center experience. Ustaalioglu BB, Gumus M, Bilici A, Seker M, Ustaalioglu R, Kefeli U, Salepci T, Canpolat N, Mayadagli A, Dogusoy I. J BUON. 2010 Jul-Sep;15(3):529-36.
5. The role of (18)F-FDG PET/CT in the assessment of suspected recurrent gastric cancer after initial surgical resection: can the results of FDG PET/CT influence patients’ treatment decision making? Bilici A, Ustaalioglu BB, Seker M, Kefeli U, Canpolat N, Tekinsoy B, Ozugur S, Gumus M. Eur J Nucl Med Mol Imaging. 2010 Sep 14.
6. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management? Bilici A, Ustaalioglu BB, Seker M, Canpolat N, Tekinsoy B, Salepci T, Gumus M. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1259-69. Epub 2010 Mar 23.
7. F-18 FDG PET/CT imaging in recurrent mantle cell lymphoma presenting with cauda equina syndrome. Bilici A, Ustaalioglu BB, Seker M, Canpolat N, Gumus M. Clin Nucl Med. 2010 Mar;35(3):211-2.
8. Primary non-Hodgkin lymphoma of cervix successfully treated with rituximab: positron emission tomography images before and after therapy: a case report. Ustaalioglu BB, Bilici A, Seker M, Canpolat N, Ozdemir N, Salepci T, Gumus M. Leuk Res. 2010 Apr;34(4): e108-10.
9. The role of PET-CT in the differential diagnosis of thymic mass after treatment of patients with lymphoma. Ustaalioglu BB, Seker M, Bilici A, Canpolat N, Yıldirim E, Kefeli U, Ustaalioglu R, Yilmaz BE, Salepci T, Ozdemir N, Gumus M. Case Report Med Oncol. 2011 Mar;28(1):258-64.
10. Pulmonary BALT Lymphoma successfully treated with eight cycles weekly rituximabe; report of first case and F-18 FDG PET/CT images. Bilici A, Seker M, Ustaalioglu BB, Canpolat N, Salepci T, Gumus. M. J Korean Med Sci. 2011 Apr;26(4):574-6.
11. Increased right ventricular glucose metabolism in patients with pulmonary arterial hypertension. Mehmet Mustafa Can, Cihangir Kaymaz, Ibrahim Halil Tanboga, Hacer Ceren Tokgoz, Nesrin Canpolat, Erdem Turkyilmaz, Kenan Sonmez, Nihal Ozdemir. Clin Nucl Med. 2011 Sep; 36(9) 743-8.
12. Comparison of Radio-guided Occult Lesion Localization (ROLL) and Magnetic Occult Lesion Localization (MOLL) for Non-palpable Lesions: A Phantom Model Study. Tumay Aydogan, Efe Sezgin, Sennur Ilvan, Osman Cem Yilmaz, Nesrin Aslan, Mehra Golshan, Fatih Aydogan. Clin Breast Cancer. 2020 Feb;20(1): e9-e13.
13. Primary hepatocellular carcinoma with intense 68Ga-PSMA uptake but slight 18F-FDG uptake on PET/CT imaging. Erhamamci S., Aslan N. Clin Nucl Med 2020; 45(3): e176-e177.
14. Comparative Findings Between 68Ga-PSMA and 18F-FDG PET/CT for Hepatocellular Carcinoma. Erhamamci S. Aslan N. Interesting Image Mol Imaging Radionucl Ther 2020; 29:135-138.
15. Metastatic lymph node detected by both 68Ga-DOTATATE and 18F-FDG PET/CT in a patient with Merkel cell carcinoma. Erhamamci S., Aslan N. Rev Esp Med Nucl Imagen Mol. 2021 Mar-Apr;40(2):119-120.

Presentations at International Scientific Conferences and Published in Proceedings:

• FDG PET/CT additional delayed pelvic images with oral hydration–voiding–refilling for detecting bladder wall lesions. Erhamamci S, Aslan N. Balkan Congress of Nuclear Medicine, 10-14 April 2019, Bodrum, Turkey (Poster presentation).
• Paget disease as a potential pitfall in 68Ga-PSMA PET/CT imaging for prostate cancer: three case reports. Erhamamci S, Aslan N. Annual Congress of the European Association of Nuclear Medicine, 12-16 October 2019, Barcelona, Spain. (Poster presentation).
• The physiological variants of 68Ga-PSMA uptake as a potential pitfall in 68Ga-PSMA PET/CT Interpretation: Three cases. Erhamamci S, Aslan N. Annual Congress of the European Association of Nuclear Medicine (Poster presentation). Submitted.